XML 56 R16.htm IDEA: XBRL DOCUMENT v3.25.1
Segment Reporting and Disaggregation of Relevant Expense Captions
 3 Months Ended
Mar. 31, 2025
Segment Reporting [Abstract]  
Segment Reporting and Disaggregation of Relevant Expense Captions Segment Reporting and Disaggregation of Relevant Expense Captions
Neurocrine Biosciences operates as a single global business segment dedicated to the research and development, commercialization, and sale of pharmaceuticals primarily in the U.S. for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. There were no changes to the accounting policies of the segment as disclosed in the 2024 Form 10-K.
The determination of a single business segment is consistent with the consolidated financial information regularly reviewed by the Chief Executive Officer as chief operating decision maker (CODM) in assessing segment performance and deciding how to allocate resources on a consolidated basis.
The CODM assesses performance for the segment and decides how to allocate resources based on net income that also is reported on the consolidated statements of income and comprehensive income as consolidated net income. The CODM uses net income to monitor budget and forecast versus actual results in assessing segment performance and to evaluate income generated from segment assets in deciding how to allocate resources. The measure of segment assets is reported on the consolidated balance sheets as total consolidated assets.
The following table presents information about reported segment revenues, segment profit, and significant segment expenses.
Three Months Ended
March 31,
(in millions)20252024
Revenues:
INGREZZA net product sales$545.2 $506.0 
CRENESSITY net product sales14.5 — 
Other revenues (1)
12.9 9.3 
Total revenues572.6 515.3 
Less:
Cost of revenues9.2 7.5 
Research and development:
External research and development 107.9 77.6 
Payroll and benefits75.0 57.6 
Milestones45.4 6.1 
Other research and development (2)
34.9 18.1 
Total research and development263.2 159.4 
Acquired in-process research and development0.1 6.0 
Selling, general, and administrative276.5 243.1 
Unrealized loss (gain) on equity investments30.6 (1.6)
Charges associated with convertible senior notes— 88.7 
Interest income and other, net
(21.7)(22.3)
Provision for (Benefit from) income taxes6.8 (8.9)
Net income
$7.9 $43.4 
_________________________
(1) Other revenues primarily consist of net product sales for ALKINDI and EFMODY and royalties earned on AbbVie net sales of elagolix and MTPC net sales of valbenazine.
(2) Other research and development consists of indirect costs incurred for the benefit of multiple research and development programs, including facility-based expenses (such as rent expense) and other overhead allocations.